Group 1 - Roche announced the acquisition of 89bio, Inc for a deal that could reach $3.5 billion [2] - The acquisition reflects ongoing interest in potential buyouts within the biotech and biopharma sector [2] - The Biotech Forum offers a model portfolio of 12-20 high upside biotech stocks along with trade discussions and market commentary [2] Group 2 - The Biotech Forum provides weekly research and option trades to its members [2] - The forum includes live chat features for discussing specific covered call trades [1] - Analyst disclosures indicate beneficial long positions in various biotech stocks [3]

Core Insights - BIOQUAL, Inc. reported a revenue of $48,867,753 for 2025, a decrease from $58,590,949 in 2024 [1] - The company experienced a loss before income tax of $(1,896,010) in 2025, contrasting with a profit of $476,447 in 2024 [1] - Net loss for the company was $(1,048,154) in 2025, compared to a net income of $483,481 in 2024 [1] - Basic and diluted earnings per share for common stock were both $(1.17) in 2025, down from $0.54 in 2024 [1] - The weighted average number of shares outstanding for basic earnings per share remained constant at 894,416 [1]

Meanwhile, an RFK Junior back vaccine panel now pushing for new restrictions on a combination shot for children, changing the current recommendations that allow children under four to receive the MMR vaccine. And this morning, uh the uh hepatitis B vaccine vote also was put off. They cited a lack of data, a vote expected later, also on COVID shot recommendations.All right, let's try and make sense of all this. Missouo healthcare sector strategist Jared Holles joins us here at Post 9. I guess from an investo ...

Group 1 - The article discusses the significant stock movement of ProKidney (NASDAQ: PROK), which saw its share price increase from $0.6 to over $4.5 overnight, indicating strong market interest and potential catalysts driving this valuation change [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts, integrated financial statements, and market analysis for major pharmaceutical companies [1] - Edmund Ingham, a biotech consultant with over five years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on more than 1,000 companies in the biotech, healthcare, and pharma sectors [1]

Company Overview - Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing immunotherapeutic drugs targeted to the tumor microenvironment (TME) [1] - The company utilizes a proprietary platform known as FHAB (Fully Human Albumin-Binding) for developing targeted biologic drugs [2] Upcoming Events - Raghu Rao, the Interim Chief Executive Officer, will present at the MedInvest Biotech & Pharma Conference on September 25, 2025, at 9:40 AM PT [1] - Management will also be available for one-on-one meetings with qualified investors registered for the conference [2] Technology and Product Pipeline - The FHAB technology employs a fully human single chain antibody fragment that binds to human serum albumin for targeted transport to tumor and lymphatic tissues [2] - Sonnet's lead program, SON-1010 (IL-12-FHAB), is in development for treating solid tumors, certain sarcomas, and ovarian cancer, currently in a Phase 1/2a study in collaboration with Roche [3] - The second program, SON-1210 (IL12-FHAB-IL15), is being evaluated for solid tumors, with an upcoming investigator-initiated Phase 1/2a study for pancreatic cancer [3]

LONDON, UK / ACCESS Newswire / September 19, 2025 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. ...

Core Insights - Polyrizon Ltd. has submitted a full pre-submission package to the FDA for its PL-14 product aimed at treating nasal allergies, marking a significant step in its regulatory strategy [1][3] - The PL-14 Allergy Blocker is a non-invasive nasal spray that creates a physical barrier to provide rapid and long-lasting relief from allergic rhinitis symptoms [2][3] - The CEO of Polyrizon emphasized the potential of PL-14 to transform treatment options for the hundreds of millions affected by allergic rhinitis globally [3] Company Overview - Polyrizon is a biotechnology company focused on developing innovative medical device hydrogels delivered as nasal sprays, which act as a barrier against viruses and allergens [3] - The company utilizes proprietary Capture and Contain TM hydrogel technology, which consists of naturally occurring building blocks, to create a protective shield in the nasal cavity [3] - Polyrizon is also developing additional technologies for nasal delivery of active pharmaceutical ingredients, referred to as Trap and Target ™ [3]

Core Viewpoint - Vaxart, Inc. has officially withdrawn its reverse stock split proposal and will focus on advancing its oral recombinant vaccine platform to create long-term value for stockholders [1][2]. Company Overview - Vaxart is a clinical-stage biotechnology company developing oral recombinant vaccines using a proprietary delivery platform that allows for storage and shipping without refrigeration [3]. - The company's vaccine candidates include those targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [3]. - Vaxart has filed broad domestic and international patent applications for its oral vaccination technology [3].

Market Overview - U.S. stock index futures are showing mixed performance as investors react to a recent Federal Reserve interest rate cut and anticipate upcoming economic data [1][2] - Major indexes closed at record highs on Thursday, with the Dow Jones Industrial Average up 0.27%, S&P 500 rising 0.48%, and Nasdaq Composite increasing by 0.94% [3] Economic Indicators - The 10-year Treasury yield rose by 2 basis points to 4.13%, while the 2-year yield increased by 1 basis point to 3.58% [2] - Strong labor market data indicated a drop in U.S. Weekly Initial Jobless Claims to 231K for the week ending September 13, below expectations, which reassured investors about economic stability [3] Upcoming Economic Data - Key economic data releases include Flash Purchasing Managers' Index (PMI) surveys and the U.S. core Personal Consumption Expenditures (PCE) price index, scheduled for September 26, 2025 [5] - Other significant upcoming data includes revised GDP numbers, consumer confidence data, home sales figures, durable goods orders, and inventories [5] Corporate Earnings - Several companies are set to report earnings, including MoneyHero Limited, IperionX Limited ADR, and FedEx, which reported better-than-expected FQ1 earnings and projected 4%-6% revenue growth for fiscal year 2026 [6][11] - 22nd Century Group's shares surged 31% after announcing it is now debt-free, while 89bio's shares skyrocketed 85% following Roche's agreement to acquire the biotech firm for $14.50 per share [11] Key Corporate News - Nvidia shares advanced 3.5% after announcing a $5 billion investment in Intel, which saw its stock surge over 23% [7] - CoreWeave's shares rose 0.3% after Loop Capital initiated coverage with a "Buy" rating, highlighting its growing prominence among chip giants and AI labs [11] - FedEx's strong results positively impacted UPS, which saw its stock increase by 2% [11] Stock Movements - Red Cat Holdings' shares fell 12% after pricing an offering of 15.6 million shares at $9.60 each [11] - Nucor's shares slipped 4% after guiding its Q3 EPS to $2.05-$2.15, below the consensus estimate of $2.56 [11]

Core Viewpoint - Jasper Therapeutics, Inc. has announced a public offering of common stock and warrants to raise approximately $30 million to support the development of briquilimab, a novel antibody therapy targeting mast cell driven diseases [1][3]. Group 1: Offering Details - The offering includes 11,670,707 shares of common stock priced at $2.43 per share, along with common warrants to purchase the same number of shares [1]. - Additionally, the offering includes pre-funded warrants for 675,000 shares, priced at $2.43 minus a nominal exercise price of $0.0001 per share [1][2]. - The gross proceeds from the offering are expected to be around $30 million, before deducting underwriting discounts and commissions [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the advancement of briquilimab's preclinical and clinical development programs, as well as for general corporate purposes, including capital expenditures and working capital [3]. Group 3: Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [7]. - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [7]. - The company is currently conducting clinical studies demonstrating the efficacy and safety of briquilimab in patients with CSU and CIndU [7].